Vericel Receives First Payment from Innovative Cellular Collaboration

Vericel initiated its collaboration with Innovative Cellular Therapeutics (ICT) following a US $5.1MM upfront payment. In 2Q17, the companies entered a license agreement whereby ICT will exclusively develop and distribute Carticel® and MACI® in Greater China, Singapore, South Korea and other countries in the region.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us